DENTSPLY SIRONA Inc. (XRAY) Upgraded to Outperform at Barrington Research

Barrington Research upgraded shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) from a market perform rating to an outperform rating in a research note released on Monday morning, Marketbeat Ratings reports. Barrington Research currently has $73.00 price target on the medical instruments supplier’s stock. Barrington Research also issued estimates for DENTSPLY SIRONA’s Q1 2018 earnings at $0.62 EPS, Q2 2018 earnings at $0.71 EPS, Q3 2018 earnings at $0.76 EPS, Q4 2018 earnings at $0.85 EPS, FY2018 earnings at $2.95 EPS and FY2019 earnings at $3.35 EPS.

XRAY has been the topic of a number of other reports. HC Wainwright reissued a buy rating and issued a $68.00 price objective (down from $74.00) on shares of DENTSPLY SIRONA in a research note on Monday, August 14th. Stifel Nicolaus reissued a buy rating and issued a $66.00 price objective (down from $70.00) on shares of DENTSPLY SIRONA in a research note on Thursday, August 10th. UBS AG reissued a neutral rating and issued a $59.00 price objective (down from $62.00) on shares of DENTSPLY SIRONA in a research note on Thursday, August 10th. TheStreet downgraded DENTSPLY SIRONA from a b rating to a c+ rating in a research note on Wednesday, August 9th. Finally, Robert W. Baird set a $63.00 price objective on DENTSPLY SIRONA and gave the company a buy rating in a research note on Thursday, October 19th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $67.00.

DENTSPLY SIRONA (XRAY) traded down $0.23 on Monday, hitting $65.33. The stock had a trading volume of 602,881 shares, compared to its average volume of 2,360,000. DENTSPLY SIRONA has a 52 week low of $52.53 and a 52 week high of $67.95. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.32 and a quick ratio of 1.59. The stock has a market cap of $14,920.00, a P/E ratio of 25.70, a PEG ratio of 2.55 and a beta of 1.27.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.04. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $978.99 million. During the same period last year, the business earned $0.66 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. equities analysts forecast that DENTSPLY SIRONA will post 2.66 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “DENTSPLY SIRONA Inc. (XRAY) Upgraded to Outperform at Barrington Research” was reported by BBNS and is the sole property of of BBNS. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://baseballnewssource.com/markets/dentsply-sirona-inc-xray-upgraded-to-outperform-at-barrington-research/1762598.html.

A number of hedge funds and other institutional investors have recently modified their holdings of XRAY. Bessemer Group Inc. increased its position in DENTSPLY SIRONA by 4,638.6% in the 3rd quarter. Bessemer Group Inc. now owns 1,903,596 shares of the medical instruments supplier’s stock worth $113,855,000 after buying an additional 1,863,424 shares during the period. Principal Financial Group Inc. increased its position in DENTSPLY SIRONA by 22.3% in the 2nd quarter. Principal Financial Group Inc. now owns 6,474,432 shares of the medical instruments supplier’s stock worth $419,802,000 after buying an additional 1,181,547 shares during the period. Parnassus Investments CA increased its position in DENTSPLY SIRONA by 62.7% in the 3rd quarter. Parnassus Investments CA now owns 2,115,000 shares of the medical instruments supplier’s stock worth $126,498,000 after buying an additional 815,000 shares during the period. Balyasny Asset Management LLC increased its position in DENTSPLY SIRONA by 415.5% in the 2nd quarter. Balyasny Asset Management LLC now owns 800,937 shares of the medical instruments supplier’s stock worth $51,933,000 after buying an additional 645,564 shares during the period. Finally, Vanguard Group Inc. increased its position in DENTSPLY SIRONA by 2.5% in the 2nd quarter. Vanguard Group Inc. now owns 22,728,062 shares of the medical instruments supplier’s stock worth $1,473,688,000 after buying an additional 562,993 shares during the period. 93.71% of the stock is currently owned by institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with our FREE daily email newsletter.

 


Latest News

MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Brandon Morrow Becomes Hot Commodity
Brandon Morrow Becomes Hot Commodity


Leave a Reply

 
© 2006-2017 BBNS.